You are here
December 7, 2013
Genetically Modified Immune Cells Attack Leukemia in Adults and Children
Three and a half years after beginning a clinical trial, supported by the National Institutes of Health, which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia announced the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, were presented on Saturday, December 7, 2013 during the American Society of Hematology's Annual Meeting and Exposition in New Orleans.
This page last reviewed on April 20, 2015